Exendin-4 potently decreases ghrelin levels in fasting rats

Diabetes

Volumn 56, Issue 1, 2007, Pages 143-151

  Pérez Tilve, Diego ^a   González Matías, Lucas ^a   Alvarez Crespo, Mayte ^a   Leiras, Roberto ^a   Tovar, Sulay ^b   Diéguez, Carlos ^b   Mallo, Federico ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; EXENDIN 3; EXENDIN 4; EXENDIN[3-39]; EXENDIN[9-39]; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [1-37]; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; LEPTIN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENCY; FEEDING BEHAVIOR; FOOD INTAKE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RAT;

ANIMALS; CEREBRAL VENTRICLES; FASTING; HUMANS; INJECTIONS, INTRAVENTRICULAR; KINETICS; MALE; PEPTIDE HORMONES; PEPTIDES; PRADER-WILLI SYNDROME; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

EID: 33847016111     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-0996     Document Type: Article

References (50)

1. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 407:908-913, 2000
2. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-1630, 2002
3. Moesgaard SG, Ahren B, Carr RD, Gram DX, Brand CL, Sundler F: Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach. Regul Pept 120:261-267, 2004
4. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325-4328, 2000
5. Gualillo O, Lago F, Gomez-Reino J, Casanueva FF, Dieguez C: Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 552:105-109, 2003
6. Ishii S, Kamegai J, Tamura H, Shimizu T, Sugihara H, Oikawa S: Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology 143:4934-4937, 2002
7. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643-644, 2002
8. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA: High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 87:5461-5464, 2002
9. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660, 1999
10. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940, 2003
11. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA: Differential effects of acute and extended infusions of glucagon-like peptide-1 on first-and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26:791-798, 2003
12. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
13. Navarro, M, Rodriquez de FF, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blazquez, E: Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982-1991, 1996
14. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ: Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29:501-505, 1994
15. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB: Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-G927, 1997
16. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, az-Miguel M, Valverde I: Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33:73-77, 2001
17. Djurhuus CB, Hansen TK, Gravholt C, Orskov L, Hosoda H, Kangawa K, Jorgensen JO, Holst JJ, Schmitz O: Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res 34:411-413, 2002
18. Lippl F, Kircher F, Erdmann J, Allescher HD, Schusdziarra V: Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regul Pept 119:93-98, 2004
19. Thorens B: Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89:8641-8645, 1992
20. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-2978, 1996
21. Mentlein R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999
22. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589, 2001
23. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290, 2002
24. Doggrell SA: Is exenatide advancing the treatment of type 2 diabetes? Expert Opin Pharmacother 7:109-112, 2006
25. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941, 2000
26. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161, 2001
27. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego, CA, Academic Press, 1998, p. 22
28. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N: The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802-807, 2000
29. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC: Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-371, 1983
30. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655, 1993
31. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S: Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 166:2041-2048, 2001
32. Hinke SA, Manhart S, Kuhn-Wache K, Nian C, Demuth HU, Pederson RA, McIntosh CH: [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem 279:3998-4006, 2004
33. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP: Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300, 1995
34. Ueno N, Dube MG, Inui A, Kalra PS, Kalra SP: Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology 145:4176-4184, 2004
35. Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G: Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 124:1188-1192, 2003
36. Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M: Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 8:317-323, 2000
37. Kastin AJ, Akerstrom V: Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27:313-318, 2003
38. Yang H, Egan JM, Wang Y, Moyes CD, Roth J, Montrose MH, Montrose-Rafizadeh C: GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275:C675-C683, 1998
39. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG: Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172:275-283, 1997
40. Baggio LL, Huang Q, Brown TJ, Drucker DJ: Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558, 2004
41. Malendowicz LK, Nowak KW: Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals. Int J Mol Med 10:327-331, 2002
42. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258, 1996
43. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Hansotia T, Drucker DJ, Wollheim C, Burcelin R, Thorens B: Glucoincretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113:635-645, 2004
44. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47:1046-1052, 1998
45. Sun Y, Ahmed S, Smith RG: Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23:7973-7981, 2003
46. Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ, Sleeman MW: Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 101:8227-8232, 2004
47. Shuto Y, Shibasaki T, Otagiri A, Kuriyama H, Ohata H, Tamura H, Kamegai J, Sugihara H, Oikawa S, Wakabayashi I: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 109:1429-1436, 2002
48. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310:996-999, 2005
49. Choe YH, Song SY, Paik KH, Oh YJ, Chu SH, Yeo SH, Kwon EK, Kim EM, Rha MY, Jin DK: Increased density of ghrelin-expressing cells in the gastric fundus and body in Prader-Willi syndrome. J Clin Endocrinol Metab 90:5441-5445, 2005
50. Gabriel JM, Merchant M, Ohta T, Ji Y, Caldwell RG, Ramsey MJ, Tucker JD, Longnecker R, Nicholls RD: A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and angelman syndromes. Proc Natl Acad Sci U S A 96:9258-9263, 1999